Skip to main content
Erschienen in: Journal of Translational Medicine 1/2022

Open Access 01.12.2022 | Research

Global research trends on the links between the gut microbiome and cancer: a visualization analysis

verfasst von: Sa’ed H. Zyoud, Samah W. Al-Jabi, Riad Amer, Muna Shakhshir, Moyad Shahwan, Ammar A. Jairoun, Maha Akkawi, Adham Abu Taha

Erschienen in: Journal of Translational Medicine | Ausgabe 1/2022

Abstract

Background

Significant links between the microbiota and human health have emerged in the last 20 years. A correlation has recently been demonstrated between changes in the gut microbiota and the development of cancer. This study aimed to use bibliometric analysis of the published gut microbiome and cancer literature to present the research status and summarize the hotspots for frontier studies.

Methods

A literature search for research on the gut microbiome and cancer research from 2001 to 2020 was conducted using the Scopus database on 20 March 2021. VOSviewer software (version 1.6.16) was used to perform the visualization analysis.

Results

From 2001 to 2020, a total of 2061 publications were retrieved. Annual publication output grew from 10 in 2001 to 486 in 2020. The USA had the largest number of publications, making the largest contribution to the field (n  = 566, 27.46%). Before 2016, most studies focused on the ‘effect of probiotics on cancer’. The latest trends showed that ‘microbiota composition and gene expression’ and ‘host-microbiome interaction in cancer immunotherapy’ would be more concerned more widely in the future.

Conclusions

Research on ‘microbiota composition and gene expression’ and ‘host-microbiome interaction in cancer immunotherapy’ will continue to be the hotspot. Therefore, this study provides the trend and characteristics of the literature on the gut microbiota and cancer literature, which provided a useful bibliometric analysis for researchers to conduct further research.
Hinweise

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Abkürzungen
IFs
Impact factors
JCR
Journal citation reports
MeSH
Medical subject headings

Background

Cancer is a multifaceted disease that is the second leading cause of death in the world [1]. Numerous studies in recent years have highlighted the dual role of the gut microbiota in maintaining host health [2, 3]. Gut bacteria can generate various metabolites and bioproducts that are essential for maintaining homeostasis in both the host and the gut [2]. The gut microbiota has been implicated in cancer and has been demonstrated to alter the effectiveness of anticancer drugs [46]. Resistance to chemo drugs or immune checkpoint inhibitors is associated with altered gut microbiota, while supplementation with different bacterial organisms restores anticancer drug responses [6]. As a result, researchers are looking at manipulating the intestinal microbiota with antibiotics, probiotics, prebiotics, or fecal transplantation to increase the effectiveness of anticancer drug effectiveness and reduce toxicity [79].
The status of research and scientific output on the gut microbiota and cancer is unknown. This is hypothesized and expected to be in progress, as shown in other microbiota science, such as trends in the research field of the gut microbiota [10], intestinal microbiota in obesity [11, 12], microbiome-gut-brain axis [13], gut microbiota and depression [14], microbiota of diabetes research [15], and fecal microbiota transplantation [16]. In addition, bibliometric research has recently been published in various scientific disciplines [1725]. Bibliometric analysis differs from systematic reviews in which systematic reviews attempt to answer a specific research question based on a small number of publications [2628]. In contrast, bibliometric analysis aims to answer a specific research question based on a large number of publications [29]. It also varies from scoping reviews, which are designed to determine the type and scope of research evidence [30, 31]. Despite these limitations, the bibliometric analysis gives a valuable overview of a field’s national and worldwide contributions to literature. It also offers baseline data, which helps to identify research gaps that might be addressed in future studies [32].
To our knowledge, only one bibliometric research was specifically based on the microbiota and restricted to gastric cancer, with data collected from the Web of Science (WoS) database [33]. As a result, to date, no comprehensive evaluation of the current literature on gut microbiota and cancer has been performed or published. Therefore, this study aimed to provide an overview of research activity on microbiota and cancer at the global level in terms of bibliometric indices. Furthermore, this study covers the latest developments, hotspots for frontier studies, and future research advancement patterns in this area. In addition, future paths and patterns in this field are forecast based on the evaluation of research output in microbiota and cancer papers.

Methods

Data sources

For source publication retrieval, the Scopus database was chosen as the target database. Scopus is widely recognized as one of the best online databases for bibliometric research [34, 35].

Search strategies

We used the Scopus online database’s “Advanced search” feature and inserted the appropriate keywords to find relevant literature on microbiota and cancer from the last 2 decades (from January 2001 to December 31, 2020). To prevent bias caused by ongoing database updates, document extraction and export should be done within 1 day (March 19, 2021). Synonyms for the gut microbiota and cancer were used as in the following search strategy.

Step 1

To achieve the objectives of this bibliometric analysis, terms related to the microbiota entered into the Scopus engine were chosen from the literature related to the microbiota [10, 11, 1316, 33]. The following ‘terms’ were used in the ‘Article Title’: ‘Bifidobacterium’ OR ‘dysbiosis’ OR ‘Escherichia coli’ OR ‘flora’ OR ‘Lactobacillus’ Microbiome’ OR ‘microbiota’ OR ‘microflora’ OR ‘probiotic’ OR ‘Saccharomyces’.

Step 2

After that, we limited the publications found in Step 1 to those that included the terms “cancer and associated terms” in their title. Terms related to cancer that were entered into the Scopus engine were extracted from the Medical Subject Headings (MeSH) from PubMed. The following ‘terms’ were entered as ‘Article Title’: ‘Neoplasia’ OR ‘Neoplasia’ OR ‘Neoplasm’ OR ‘Tumor’ OR ‘Cancer’ OR “Malignancy” OR ‘carcinoma’ OR ‘Malignancies’ OR ‘Malignant’.

Bibliometric analysis

An Excel spreadsheet was used to collect the following data as bibliometric indicators: total number of publications, year of publication, publication types, to ten funding agencies, top ten countries, top ten institutions, top ten journals, most cancer types related to microbiota based in the top keyword, and top ten citations.

Visualise analysis

The VOSviewer software tool (version 1.6.16) was used to build, visualize and explore networks of countries, authors, and terms, with links between items based on their cooccurrences [36, 37], was applied to create network visualization maps of the most cooccurrence terms to determine the hotspots for frontier studies, as well as the most coauthorships of countries.

Results

General description of the retrieved publications

In total, 2061 publications were included in this study. Articles made up 1346 of the total number of publications, accounting for 65.31% of the total number of records, making them the most popular form of literature. There were 511 reviews, representing 24.79 percent of the total. The other eight types of publications were 204 documents, representing 9.90% of the total, including letters, book chapter, notes, book, editorials, minutes of meetings, erratum, and short surveys.
During the past 2 decades, the number of microbiota and cancer publications increased yearly, from 10 in 2001 to 486 in 2020, as shown in Fig. 1. The growth of the publication showed two stages: the first (2001–2016), which had a very slow rate of publication production, and the second (2017–2020), which had a much faster rate of publication progress.

Top active countries

At least 112 different countries participated in the publication of studies on the microbiota and cancer in the last 2 decades. A total of 1568 articles written in the top ten countries represented 70.8% of all studies in the related area (Table 1). The United States (n = 566) was the largest contributor, followed by China (n = 478), Italy (n = 135), Japan (n = 122) and the United Kingdom (n = 94). In addition, the United States and China had the largest number of publications involving international scholars. Figure 2 shows a network mapping chart of international research collaborations on microbiota and cancer from 2001 to 2020 among the leading participating countries. The total number of authors published on microbiota and cancer was 9102, of which 25 published more than 15 documents.
Table 1
List of the top 10 countries publishing research on microbiota and cancer from 2001 to 2020
Ranking
Country
Number of documents
%
1st
United States
566
27.46
2nd
China
478
23.19
3rd
Italy
135
6.55
4th
Japan
122
5.92
5th
United Kingdom
94
4.56
6th
Iran
91
4.42
7th
France
83
4.03
8th
Germany
82
3.98
9th
South Korea
74
3.59
10th
Canada
63
3.06

Top active institutions

The Institut National de la Santé et de la Recherche Médicale (INSERM) in France had the highest number of publications among institutions worldwide, with 40 publications, which accounted for 1.94% of all publications. The National Cancer Institute of the USA was the second prolific institute with 35 (1.70%) publications, followed by the MD Anderson Cancer Center of the University of Texas in the USA with 30 (1.46%) publications, the Ministry of Education of China with 28 (1.36%) and the University of North Carolina at Chapel Hill in the USA with 28 (1.36%) publications (Table 2).
Table 2
List of the top 10 institutions publishing research on microbiota and cancer from 2001 to 2020
Ranking
Institute
Country
n
%
1st
INSERM
France
40
1.94
2nd
National Cancer Institute NCI
USA
35
1.70
3rd
University of Texas MD Anderson Cancer Center
USA
30
1.46
4th
Ministry of Education China
China
28
1.36
4th
The University of North Carolina at Chapel Hill
USA
28
1.36
6th
National Institutes of Health NIH
USA
27
1.31
6th
Tehran University of Medical Sciences
Iran
27
1.31
8th
Harvard Medical School
USA
26
1.26
9th
Tabriz University of Medical Sciences
Iran
25
1.21
10th
Zhejiang University
China
24
1.16
10th
Universite Paris-Saclay
France
24
1.16

Top funding agencies

Of the documents that were retrieved, USA funding agencies were the most active in this field, the National Natural Science Foundation of China (n = 211; 10.24%) being the most active, followed by the National Cancer Institute (n = 186; 9.02%), National Institutes of Health (n = 163; 7.91%) and the National Institute of Diabetes and Digestive and Kidney Diseases (n = 80; 3.88%) (Table 3).
Table 3
The top ten funding agencies having the most publications on microbiota and cancer from 2001 to 2020
Ranking
Funding agencies
Country
Number of publication
%
1st
National Natural Science Foundation of China
China
211
10.24
2nd
National Cancer Institute
USA
186
9.02
3rd
National Institutes of Health
USA
163
7.91
4th
National Institute of Diabetes and Digestive and Kidney Diseases
USA
80
3.88
5th
Japan Society for the Promotion of Science
Japan
48
2.33
6th
National Institute of Allergy and Infectious Diseases
USA
33
1.60
7th
European Commission
European Union
30
1.46
8th
National Institute of General Medical Sciences
China
25
1.21
9th
Ministry of Education, Culture, Sports, Science and Technology
Japan
24
1.16
10th
National Research Foundation of Korea
Korea
24
1.16

Top active journals

The top 10 journals with the most publications related to microbiota and cancer are listed in Table 4. Scientific Reports had the highest number of publications among journals worldwide, with 40 publications representing 1.94% of all publications. The International Journal of Molecular Sciences and PloS ONE were the second with 33 (1.6%) publications for each journal, followed by Frontiers in Microbiology with 27(1.31%) publications.
Table 4
List of the top 10 journals publishing research on microbiota and cancer from 2001 to 2020
Ranking
Journal
Frequency
%
IFa
1st
Scientific Reports
40
1.94
3.998
2nd
International Journal of Molecular Sciences
33
1.60
4.556
3rd
PloS ONE
33
1.60
2.740
4th
Frontiers in Microbiology
27
1.31
4.235
5th
Cancers
23
1.12
6.126
6th
Frontiers in Oncology
20
0.97
4.848
7th
Journal of Functional Foods
19
0.92
3.701
8th
Gut
18
0.87
19.819
9th
Gut Microbes
18
0.87
7.740
10th
Nutrition and Cancer
17
0.82
2.363
SCR standard competition ranking; IF impact factor
aImpact factors based on the 2019 Journal Citation Reports 2019 from Clarivate Analytics

Top-cited publications

Table 5 summarizes the top ten most cited papers in the microbiota and cancer during the last 2 decades based on total citations. The top 10 highest citations ranged from 1378 to 441 [3847]. Routy et al. [44], published in Science in 2018, had the highest overall citation frequency (number of citations = 1378) among the top ten publications with total citation frequency.
Table 5
Top cited list of the top 10 high cited papers related to microbiota and cancer from 2001 to 2020
Ranking
Authors
Year
Source title
Cited by
1st
Routy et al. [44]
2018
Science
1378
2nd
Arthur et al. [38]
2012
Science
1023
3rd
Louis et al. [42]
2014
Nature Reviews Microbiology
966
4th
Schwabe and Jobin [45]
2013
Nature Reviews Cancer
702
5th
Dapito et al. [40]
2012
Cancer Cell
592
6th
Wang et al. [47]
2012
ISME Journal
555
7th
Sobhani [46]
2011
PLoS ONE
493
8th
Martin et al. [43]
2004
Gastroenterology
481
9th
Chen et al. [39]
2012
PLoS ONE
449
10th
Garret [41]
2015
Science
441

Hotspots for frontier studies

Terms with a minimum number of occurrences greater than 50 in all included publications were analyzed using VOSviewer. There are 109 terms that reach this threshold out of 34,784 in this field, which were divided into three clusters and colored differently. The three clusters are “microbiota composition and gene expression” (cluster 1, green), “effect of probiotics on cancer” (cluster 2, red), and “host-microbiome interaction in cancer immunotherapy” (cluster 3, blue); (Fig. 3). In cluster 1, the most striking keywords are sequence, abundance, composition, healthy control, and patient. In cluster 2, the most common keywords are effect, probiotic, ability, apoptosis, proliferation, reduction, cancer cell, and inhibition. In cluster 3, the keywords with the most repetition are microbiome, evidence, pathogenesis, cancer, immunotherapy, interaction, cancer therapy, and immunity. These results demonstrated that the most prominent fields of microbiota and cancer included 3 directions during the past 20 years. Keywords were color coded by VOSviewer based on the average time they appeared in the 2061 related publications (Fig. 4). The terms in blue appeared earlier, and those in yellow and green appeared later. Before 2016, most studies focused on the ‘effect of probiotics on cancer’. The latest trends showed that ‘microbiota composition and gene expression’ and ‘host-microbiome interaction in cancer immunotherapy’ would be more concerned more widely in the future.

The most frequent cancer types encountered in the retrieved literature

Table 6 lists the most frequent keywords related to cancer types occurrences in microbiota literature from 2001 to 2020. The top keywords indicate that colorectal cancer is strongly related to microbiota in the literature, followed by breast cancer, stomach cancer, and lung cancer (Table 6).
Table 6
List of most frequent keywords related to cancer types occurrences in microbiota literature from 2001 to 2020
Cancer types
Frequency
%
Colorectal cancer
559
27.12
Colorectal neoplasms
347
16.84
Colorectal tumor
280
13.59
Colon cancer
191
9.27
Colonic neoplasms
150
7.28
Breast cancer
124
6.02
Colon tumor
111
5.39
Stomach cancer
103
5.00
Breast neoplasms
79
3.83
Gastrointestinal cancers
78
3.78
Lung cancer
78
3.78

Discussion

This is the first bibliometric study to evaluate and visualize research of the gut microbiota in the field of oncology. A total of 2061 publications originating from the Scopus database were analyzed. We offer a detailed analysis of global trends and hotspots in gut microbiota and cancer research over the past 2 decades. According to our study, publications have increased rapidly since 2017.
Previous research on microbiota and gastric cancer [33] found findings that differed from those presented in our study (196 documents worldwide from 2000 to 2019). The inconsistency was attributable to (1) the various databases used to access the publications and (2) the different research domains analyzed. Zhang et al. [33] study was carried out using WoS and was limited to gastric cancer. In our study, the Scopus database used more comprehensive terms related to gut microbiota and cancer without limiting the results to any particular cancer. We conducted our bibliometric research using the Scopus database, which Elsevier owns. According to several studies, Scopus is the world’s largest database of abstracts and citations from peer-reviewed scientific literature [4850]. Various scholars for bibliometric evaluation of various fields of science [4852]. Scopus is a multidisciplinary database that has more indexed journals than PubMed and WoS [5355].
The United States was the leading contributor in this field with 566 publications, followed by China, Italy, Japan, and the United Kingdom. Research success in these countries can be linked to a diverse group of researchers with expertise in this area and a significant amount of financial funding for researchers. This research productivity is not unexpected, considering that it is in countries with stronger infrastructures, more abundant scientific services, and a long history in the general study of the microbiome. Many experts in the fields of microbiology, oncology, and gastroenterology (eg., Marchesi JR, Jobin C, Trinchieri G, Perdigón G, Qin H, Gao R, Wargo JA, White JR, Zitvogel L, Ahn J, Fujimori M, Goedert JJ, Mahdavi M, Morrow CD, Oue N, Sentani K, Sobhani I, Yasui W, Yu J, Zitvogel L, and others) are gaining interest in the pathological function and host-microbiome relationship in cancer as an evolving forum to evaluate the diagnosis and effective therapeutic intervention of these ailments, which is possibly contributing to the increase in research productivity [5668].
Furthermore, the increase in the number of publications on microbiota and cancer may be linked to many hot topics published during this time frame, exposing innovative theories that lead to new fields of research. These findings suggest new therapeutic and diagnostic concepts for various disorders in the field of oncology [3847, 6973] such as “effect of probiotics on cancer”, “microbiota composition and gene expression” and “host-microbiome interaction in cancer immunotherapy”.
The results of our study indicate that the most highly cited microbiota and cancer publications emphasized on a variety of subtopics close to the study hotspots in co-occurring terms, which is a strong trend emerging from the results. The article most cited was Routy et al. [44] entitled ‘Gut microbiome influences the efficacy of PD-1-based immunotherapy against epithelial tumors’, published in Science in 2018, with 1,378 total citations. This study reported that the maintenance of healthy gut flora could affect patient responses to cancer immunotherapy and help patients combat cancer. The second paper was by Arthur et al. [38] from Science. The complex effects of inflammation on the microbial composition/activity and the host’s ability to defend itself from a dysbiotic microbiota were illustrated in this report [38]. The third most cited paper is a study by Louis et al. [42] in Nature Reviews Microbiology as a review, which discusses the relationship between microbial metabolism, diet, and colorectal cancer, and argues that the cumulative effects of microbial metabolites should be considered to help predict and prevent cancer progression.

Strengths and limitations

The current study is the first bibliometric study of its kind to look at this emerging topic and provide comprehensive information on research trends and hotspots in this field. Three elements of current research are unique: (1) the use of Scopus, the largest database available; (2) the use of terms related to the gut microbiota and cancer comprehensively; and (3) it is global in scope. Finally, the findings of our research have some limitations. First, this study’s analysis is based on papers found in the Scopus database. Although this database contains most of the majority of research papers on gut microbiota and cancer, other databases such as PubMed and WoS may have some publications related to our topic, which is a weakness of this article. Second, the fact that we only included publications on cancer or gut microbiota in the article title has an inherent flaw; our experience has shown that including search items in the abstract has a much lower sensitivity and would have only found a small number of additional papers, if any. If we include terms from the abstract in our search query without any restrictions, we will get a lot of irrelevant publications that are not related to our subject. Despite these limitations, we believe that the findings provide a reliable representation of the performance of the gut microbiota and cancer research at a global level.

Conclusions

This study shows the current status of microbiota and cancer on a global level and the hottest directions. According to the pattern in recent years, there will be a rise in the number of publications in this field. Until now, the United States and China have made the most significant contributions in the field of microbiota and cancer. Research on ‘microbiota composition and gene expression’ and ‘host-microbiome interaction in cancer immunotherapy’ will continue to be the hotspot. This serves as a starting point for further debate, while also emphasizing the need for further analysis.

Acknowledgements

Not applicable.

Declarations

There was no need for ethical approval because the data for the bibliometric research were extracted directly from the database without further human intervention.
Not applicable.

Competing interests

The authors declare that they have no competing interests.
Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://​creativecommons.​org/​licenses/​by/​4.​0/​. The Creative Commons Public Domain Dedication waiver (http://​creativecommons.​org/​publicdomain/​zero/​1.​0/​) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Literatur
1.
Zurück zum Zitat GBD 2015 Mortality and Causes of Death Collaborators. Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980–2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet. 2016;388(10053):1459–544. GBD 2015 Mortality and Causes of Death Collaborators. Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980–2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet. 2016;388(10053):1459–544.
3.
Zurück zum Zitat Gaucher L, Adda L, Séjourné A, Joachim C, Guillaume C, Poulet C, Liabeuf S, Gras-Champel V, Masmoudi K, Houessinon A, et al. Associations between dysbiosis-inducing drugs, overall survival and tumor response in patients treated with immune checkpoint inhibitors. Ther Adv Med Oncol. 2021;13:17588359211000592.PubMedPubMedCentral Gaucher L, Adda L, Séjourné A, Joachim C, Guillaume C, Poulet C, Liabeuf S, Gras-Champel V, Masmoudi K, Houessinon A, et al. Associations between dysbiosis-inducing drugs, overall survival and tumor response in patients treated with immune checkpoint inhibitors. Ther Adv Med Oncol. 2021;13:17588359211000592.PubMedPubMedCentral
4.
Zurück zum Zitat Iida N, Dzutsev A, Stewart CA, Smith L, Bouladoux N, Weingarten RA, Molina DA, Salcedo R, Back T, Cramer S, et al. Commensal bacteria control cancer response to therapy by modulating the tumor microenvironment. Science. 2013;342(6161):967–70.PubMedPubMedCentral Iida N, Dzutsev A, Stewart CA, Smith L, Bouladoux N, Weingarten RA, Molina DA, Salcedo R, Back T, Cramer S, et al. Commensal bacteria control cancer response to therapy by modulating the tumor microenvironment. Science. 2013;342(6161):967–70.PubMedPubMedCentral
5.
Zurück zum Zitat Butterfield LH, Kaufman HL, Marincola FM. Cancer immunotherapy principles and practice. New York: Springer Publishing Company; 2021. Butterfield LH, Kaufman HL, Marincola FM. Cancer immunotherapy principles and practice. New York: Springer Publishing Company; 2021.
6.
Zurück zum Zitat Cheng WY, Wu CY, Yu J. The role of gut microbiota in cancer treatment: friend or foe? Gut. 2020;69(10):1867–76.PubMed Cheng WY, Wu CY, Yu J. The role of gut microbiota in cancer treatment: friend or foe? Gut. 2020;69(10):1867–76.PubMed
7.
Zurück zum Zitat Gori S, Inno A, Belluomini L, Bocus P, Bisoffi Z, Russo A, Arcaro G. Gut microbiota and cancer: how gut microbiota modulates activity, efficacy and toxicity of antitumoral therapy. Crit Rev Oncol Hematol. 2019;143:139–47.PubMed Gori S, Inno A, Belluomini L, Bocus P, Bisoffi Z, Russo A, Arcaro G. Gut microbiota and cancer: how gut microbiota modulates activity, efficacy and toxicity of antitumoral therapy. Crit Rev Oncol Hematol. 2019;143:139–47.PubMed
8.
Zurück zum Zitat Raza MH, Gul K, Arshad A, Riaz N, Waheed U, Rauf A, Aldakheel F, Alduraywish S, Rehman MU, Abdullah M, et al. Microbiota in cancer development and treatment. J Cancer Res Clin Oncol. 2019;145(1):49–63.PubMed Raza MH, Gul K, Arshad A, Riaz N, Waheed U, Rauf A, Aldakheel F, Alduraywish S, Rehman MU, Abdullah M, et al. Microbiota in cancer development and treatment. J Cancer Res Clin Oncol. 2019;145(1):49–63.PubMed
10.
Zurück zum Zitat Yue YY, Fan XY, Zhang Q, Lu YP, Wu S, Wang S, Yu M, Cui CW, Sun ZR. Bibliometric analysis of subject trends and knowledge structures of gut microbiota. World J Clin Cases. 2020;8(13):2817–32.PubMedPubMedCentral Yue YY, Fan XY, Zhang Q, Lu YP, Wu S, Wang S, Yu M, Cui CW, Sun ZR. Bibliometric analysis of subject trends and knowledge structures of gut microbiota. World J Clin Cases. 2020;8(13):2817–32.PubMedPubMedCentral
11.
Zurück zum Zitat Yao H, Wan JY, Wang CZ, Li L, Wang J, Li Y, Huang WH, Zeng J, Wang Q, Yuan CS. Bibliometric analysis of research on the role of intestinal microbiota in obesity. PeerJ. 2018;6:e5091.PubMedPubMedCentral Yao H, Wan JY, Wang CZ, Li L, Wang J, Li Y, Huang WH, Zeng J, Wang Q, Yuan CS. Bibliometric analysis of research on the role of intestinal microbiota in obesity. PeerJ. 2018;6:e5091.PubMedPubMedCentral
12.
Zurück zum Zitat Ejtahed HS, Tabatabaei-Malazy O, Soroush AR, Hasani-Ranjbar S, Siadat SD, Raes J, Larijani B. Worldwide trends in scientific publications on association of gut microbiota with obesity. Iran J Basic Med Sci. 2019;22(1):65–71.PubMedPubMedCentral Ejtahed HS, Tabatabaei-Malazy O, Soroush AR, Hasani-Ranjbar S, Siadat SD, Raes J, Larijani B. Worldwide trends in scientific publications on association of gut microbiota with obesity. Iran J Basic Med Sci. 2019;22(1):65–71.PubMedPubMedCentral
13.
Zurück zum Zitat Zyoud SH, Smale S, Waring WS, Sweileh WM, Al-Jabi SW. Global research trends in microbiome-gut-brain axis during 2009–2018: a bibliometric and visualized study. BMC Gastroenterol. 2019;19(1):158.PubMedPubMedCentral Zyoud SH, Smale S, Waring WS, Sweileh WM, Al-Jabi SW. Global research trends in microbiome-gut-brain axis during 2009–2018: a bibliometric and visualized study. BMC Gastroenterol. 2019;19(1):158.PubMedPubMedCentral
14.
Zurück zum Zitat Zhu X, Hu J, Deng S, Tan Y, Qiu C, Zhang M, Ni X, Lu H, Wang Z, Li L, et al. Bibliometric and visual analysis of research on the links between the gut microbiota and depression from 1999 to 2019. Front Psychiatry. 2020;11:587670.PubMed Zhu X, Hu J, Deng S, Tan Y, Qiu C, Zhang M, Ni X, Lu H, Wang Z, Li L, et al. Bibliometric and visual analysis of research on the links between the gut microbiota and depression from 1999 to 2019. Front Psychiatry. 2020;11:587670.PubMed
15.
Zurück zum Zitat Tian J, Li M, Lian F, Tong X. The hundred most-cited publications in microbiota of diabetes research: a bibliometric analysis. Medicine. 2017;96(37):e7338.PubMedPubMedCentral Tian J, Li M, Lian F, Tong X. The hundred most-cited publications in microbiota of diabetes research: a bibliometric analysis. Medicine. 2017;96(37):e7338.PubMedPubMedCentral
16.
Zurück zum Zitat Li Y, Zou Z, Bian X, Huang Y, Wang Y, Yang C, Zhao J, Xie L. Fecal microbiota transplantation research output from 2004 to 2017: a bibliometric analysis. PeerJ. 2019;7:e6411.PubMedPubMedCentral Li Y, Zou Z, Bian X, Huang Y, Wang Y, Yang C, Zhao J, Xie L. Fecal microbiota transplantation research output from 2004 to 2017: a bibliometric analysis. PeerJ. 2019;7:e6411.PubMedPubMedCentral
17.
Zurück zum Zitat Bougioukas KI, Vounzoulaki E, Mantsiou CD, Papanastasiou GD, Savvides ED, Ntzani EE, Haidich AB. Global mapping of overviews of systematic reviews in healthcare published between 2000 and 2020: a bibliometric analysis. J Clin Epidemiol. 2021;137:58–72.PubMed Bougioukas KI, Vounzoulaki E, Mantsiou CD, Papanastasiou GD, Savvides ED, Ntzani EE, Haidich AB. Global mapping of overviews of systematic reviews in healthcare published between 2000 and 2020: a bibliometric analysis. J Clin Epidemiol. 2021;137:58–72.PubMed
18.
Zurück zum Zitat Du YQ, Zhu GD, Cao J, Huang JY. Research supporting malaria control and elimination in China over four decades: a bibliometric analysis of academic articles published in chinese from 1980 to 2019. Malar J. 2021;20(1):158.PubMedPubMedCentral Du YQ, Zhu GD, Cao J, Huang JY. Research supporting malaria control and elimination in China over four decades: a bibliometric analysis of academic articles published in chinese from 1980 to 2019. Malar J. 2021;20(1):158.PubMedPubMedCentral
19.
Zurück zum Zitat Gonzalez-Alcaide G, Palacios-Fernandez S, Ramos-Rincon JM. Thematic research clusters in very old populations (>/= 80 years): a bibliometric approach. BMC Geriatr. 2021;21(1):266.PubMedPubMedCentral Gonzalez-Alcaide G, Palacios-Fernandez S, Ramos-Rincon JM. Thematic research clusters in very old populations (>/= 80 years): a bibliometric approach. BMC Geriatr. 2021;21(1):266.PubMedPubMedCentral
21.
Zurück zum Zitat Sahin S, Sivri N, Akpinar I, Cincin ZB, Sonmez VZ. A comprehensive bibliometric overview: antibiotic resistance and Escherichia coli in natural water. Environ Sci Pollut Res Int. 2021;28(25):32256–63.PubMedCentral Sahin S, Sivri N, Akpinar I, Cincin ZB, Sonmez VZ. A comprehensive bibliometric overview: antibiotic resistance and Escherichia coli in natural water. Environ Sci Pollut Res Int. 2021;28(25):32256–63.PubMedCentral
22.
Zurück zum Zitat Sweileh WM. Contribution of researchers in the Arab region to peer-reviewed literature on mental health and well-being of university students. Int J Ment Health Syst. 2021;15(1):50.PubMedPubMedCentral Sweileh WM. Contribution of researchers in the Arab region to peer-reviewed literature on mental health and well-being of university students. Int J Ment Health Syst. 2021;15(1):50.PubMedPubMedCentral
23.
Zurück zum Zitat Torres RT, Carvalho J, Cunha MV, Serrano E, Palmeira JD, Fonseca C. Temporal and geographical research trends of antimicrobial resistance in wildlife—a bibliometric analysis. One Health. 2021;11:100198.PubMed Torres RT, Carvalho J, Cunha MV, Serrano E, Palmeira JD, Fonseca C. Temporal and geographical research trends of antimicrobial resistance in wildlife—a bibliometric analysis. One Health. 2021;11:100198.PubMed
24.
Zurück zum Zitat Wang K, Duan W, Duan Y, Yu Y, Chen X, Xu Y, Chen H, Huang H, Xiong B. A bibliometric insight of genetic factors in ASD: emerging trends and new developments. Brain Sci. 2020;11(1):1–14. Wang K, Duan W, Duan Y, Yu Y, Chen X, Xu Y, Chen H, Huang H, Xiong B. A bibliometric insight of genetic factors in ASD: emerging trends and new developments. Brain Sci. 2020;11(1):1–14.
25.
Zurück zum Zitat Zyoud SH. The Arab region’s contribution to global COVID-19 research: bibliometric and visualization analysis. Global Health. 2021;17(1):31.PubMedPubMedCentral Zyoud SH. The Arab region’s contribution to global COVID-19 research: bibliometric and visualization analysis. Global Health. 2021;17(1):31.PubMedPubMedCentral
26.
Zurück zum Zitat Møller AM, Myles PS. What makes a good systematic review and meta-analysis? Br J Anaesth. 2016;117(4):428–30.PubMed Møller AM, Myles PS. What makes a good systematic review and meta-analysis? Br J Anaesth. 2016;117(4):428–30.PubMed
27.
Zurück zum Zitat O’Gorman CS, Macken AP, Cullen W, Saunders J, Dunne C, Higgins MF. What are the differences between a literature search, a literature review, a systematic review and a meta-analysis? And why is a systematic review considered to be so good? Ir Med J. 2013;106(2 Suppl):8–10.PubMed O’Gorman CS, Macken AP, Cullen W, Saunders J, Dunne C, Higgins MF. What are the differences between a literature search, a literature review, a systematic review and a meta-analysis? And why is a systematic review considered to be so good? Ir Med J. 2013;106(2 Suppl):8–10.PubMed
28.
Zurück zum Zitat Peters MD, Godfrey CM, Khalil H, McInerney P, Parker D, Soares CB. Guidance for conducting systematic scoping reviews. Int J Evid Based Healthc. 2015;13(3):141–6.PubMed Peters MD, Godfrey CM, Khalil H, McInerney P, Parker D, Soares CB. Guidance for conducting systematic scoping reviews. Int J Evid Based Healthc. 2015;13(3):141–6.PubMed
29.
Zurück zum Zitat Wallin JA. Bibliometric methods: pitfalls and possibilities. Basic Clin Pharmacol Toxicol. 2005;97(5):261–75.PubMed Wallin JA. Bibliometric methods: pitfalls and possibilities. Basic Clin Pharmacol Toxicol. 2005;97(5):261–75.PubMed
30.
31.
Zurück zum Zitat Grant MJ, Booth A. A typology of reviews: an analysis of 14 review types and associated methodologies. Health Info Libr J. 2009;26(2):91–108.PubMed Grant MJ, Booth A. A typology of reviews: an analysis of 14 review types and associated methodologies. Health Info Libr J. 2009;26(2):91–108.PubMed
32.
Zurück zum Zitat Sweileh WM, Moh’d Mansour A. Bibliometric analysis of global research output on antimicrobial resistance in the environment (2000–2019). Glob Health Res Policy. 2020;5:37.PubMedPubMedCentral Sweileh WM, Moh’d Mansour A. Bibliometric analysis of global research output on antimicrobial resistance in the environment (2000–2019). Glob Health Res Policy. 2020;5:37.PubMedPubMedCentral
33.
Zurück zum Zitat Zhang T, Yin X, Yang X, Man J, He Q, Wu Q, Lu M. Research trends on the relationship between microbiota and gastric cancer: a bibliometric analysis from 2000 to 2019. J Cancer. 2020;11(16):4823–31.PubMedPubMedCentral Zhang T, Yin X, Yang X, Man J, He Q, Wu Q, Lu M. Research trends on the relationship between microbiota and gastric cancer: a bibliometric analysis from 2000 to 2019. J Cancer. 2020;11(16):4823–31.PubMedPubMedCentral
34.
Zurück zum Zitat Baas J, Schotten M, Plume A, Côté G, Karimi R. Scopus as a curated, high-quality bibliometric data source for academic research in quantitative science studies. Quant Sci Stud. 2020;1(1):377–86. Baas J, Schotten M, Plume A, Côté G, Karimi R. Scopus as a curated, high-quality bibliometric data source for academic research in quantitative science studies. Quant Sci Stud. 2020;1(1):377–86.
35.
Zurück zum Zitat Sweileh WM. Bibliometric analysis of scientific publications on “sustainable development goals” with emphasis on “good health and well-being” goal (2015–2019). Global Health. 2020;16(1):68.PubMedPubMedCentral Sweileh WM. Bibliometric analysis of scientific publications on “sustainable development goals” with emphasis on “good health and well-being” goal (2015–2019). Global Health. 2020;16(1):68.PubMedPubMedCentral
36.
Zurück zum Zitat van Eck NJ, Waltman L. Software survey: VOSviewer, a computer program for bibliometric mapping. Scientometrics. 2010;84(2):523–38.PubMed van Eck NJ, Waltman L. Software survey: VOSviewer, a computer program for bibliometric mapping. Scientometrics. 2010;84(2):523–38.PubMed
37.
Zurück zum Zitat van Eck NJ, Waltman L. Citation-based clustering of publications using CitNetExplorer and VOSviewer. Scientometrics. 2017;111(2):1053–70.PubMedPubMedCentral van Eck NJ, Waltman L. Citation-based clustering of publications using CitNetExplorer and VOSviewer. Scientometrics. 2017;111(2):1053–70.PubMedPubMedCentral
38.
Zurück zum Zitat Arthur JC, Perez-Chanona E, Mühlbauer M, Tomkovich S, Uronis JM, Fan TJ, Campbell BJ, Abujamel T, Dogan B, Rogers AB, et al. Intestinal inflammation targets cancer-inducing activity of the microbiota. Science. 2012;338(6103):120–3.PubMedPubMedCentral Arthur JC, Perez-Chanona E, Mühlbauer M, Tomkovich S, Uronis JM, Fan TJ, Campbell BJ, Abujamel T, Dogan B, Rogers AB, et al. Intestinal inflammation targets cancer-inducing activity of the microbiota. Science. 2012;338(6103):120–3.PubMedPubMedCentral
39.
Zurück zum Zitat Chen W, Liu F, Ling Z, Tong X, Xiang C. Human intestinal lumen and mucosa-associated microbiota in patients with colorectal cancer. PLoS ONE. 2012;7(6):e39743.PubMedPubMedCentral Chen W, Liu F, Ling Z, Tong X, Xiang C. Human intestinal lumen and mucosa-associated microbiota in patients with colorectal cancer. PLoS ONE. 2012;7(6):e39743.PubMedPubMedCentral
40.
Zurück zum Zitat Dapito DH, Mencin A, Gwak GY, Pradere JP, Jang MK, Mederacke I, Caviglia JM, Khiabanian H, Adeyemi A, Bataller R, et al. Promotion of hepatocellular carcinoma by the intestinal microbiota and TLR4. Cancer Cell. 2012;21(4):504–16.PubMedPubMedCentral Dapito DH, Mencin A, Gwak GY, Pradere JP, Jang MK, Mederacke I, Caviglia JM, Khiabanian H, Adeyemi A, Bataller R, et al. Promotion of hepatocellular carcinoma by the intestinal microbiota and TLR4. Cancer Cell. 2012;21(4):504–16.PubMedPubMedCentral
42.
Zurück zum Zitat Louis P, Hold GL, Flint HJ. The gut microbiota, bacterial metabolites and colorectal cancer. Nat Rev Microbiol. 2014;12(10):661–72.PubMed Louis P, Hold GL, Flint HJ. The gut microbiota, bacterial metabolites and colorectal cancer. Nat Rev Microbiol. 2014;12(10):661–72.PubMed
43.
Zurück zum Zitat Martin HM, Campbell BJ, Hart CA, Mpofu C, Nayar M, Singh R, Englyst H, Williams HF, Rhodes JM. Enhanced Escherichia coli adherence and invasion in Crohn’s disease and colon cancer. Gastroenterology. 2004;127(1):80–93.PubMed Martin HM, Campbell BJ, Hart CA, Mpofu C, Nayar M, Singh R, Englyst H, Williams HF, Rhodes JM. Enhanced Escherichia coli adherence and invasion in Crohn’s disease and colon cancer. Gastroenterology. 2004;127(1):80–93.PubMed
44.
Zurück zum Zitat Routy B, Le Chatelier E, Derosa L, Duong CPM, Alou MT, Daillère R, Fluckiger A, Messaoudene M, Rauber C, Roberti MP, et al. Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors. Science. 2018;359(6371):91–7.PubMed Routy B, Le Chatelier E, Derosa L, Duong CPM, Alou MT, Daillère R, Fluckiger A, Messaoudene M, Rauber C, Roberti MP, et al. Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors. Science. 2018;359(6371):91–7.PubMed
46.
Zurück zum Zitat Sobhani I, Tap J, Roudot-Thoraval F, Roperch JP, Letulle S, Langella P, Corthier G, Van Nhieu JT, Furet JP. Microbial dysbiosis in colorectal cancer (CRC) patients. PLoS ONE. 2011;6(1):e16393.PubMedPubMedCentral Sobhani I, Tap J, Roudot-Thoraval F, Roperch JP, Letulle S, Langella P, Corthier G, Van Nhieu JT, Furet JP. Microbial dysbiosis in colorectal cancer (CRC) patients. PLoS ONE. 2011;6(1):e16393.PubMedPubMedCentral
47.
Zurück zum Zitat Wang T, Cai G, Qiu Y, Fei N, Zhang M, Pang X, Jia W, Cai S, Zhao L. Structural segregation of gut microbiota between colorectal cancer patients and healthy volunteers. ISME J. 2012;6(2):320–9.PubMed Wang T, Cai G, Qiu Y, Fei N, Zhang M, Pang X, Jia W, Cai S, Zhao L. Structural segregation of gut microbiota between colorectal cancer patients and healthy volunteers. ISME J. 2012;6(2):320–9.PubMed
48.
Zurück zum Zitat AlRyalat SAS, Malkawi LW, Momani SM. Comparing bibliometric analysis using PubMed, Scopus, and Web of science databases. J Vis Exp. 2019;152:e58494. AlRyalat SAS, Malkawi LW, Momani SM. Comparing bibliometric analysis using PubMed, Scopus, and Web of science databases. J Vis Exp. 2019;152:e58494.
49.
Zurück zum Zitat Zyoud SH, Al-Jabi SW. Mapping the situation of research on coronavirus disease-19 (COVID-19): a preliminary bibliometric analysis during the early stage of the outbreak. BMC Infect Dis. 2020;20(1):561.PubMedPubMedCentral Zyoud SH, Al-Jabi SW. Mapping the situation of research on coronavirus disease-19 (COVID-19): a preliminary bibliometric analysis during the early stage of the outbreak. BMC Infect Dis. 2020;20(1):561.PubMedPubMedCentral
50.
Zurück zum Zitat Sweileh WM. Bibliometric analysis of global scientific literature on vaccine hesitancy in peer-reviewed journals (1990–2019). BMC Public Health. 2020;20(1):1252.PubMedPubMedCentral Sweileh WM. Bibliometric analysis of global scientific literature on vaccine hesitancy in peer-reviewed journals (1990–2019). BMC Public Health. 2020;20(1):1252.PubMedPubMedCentral
51.
Zurück zum Zitat Sweileh WM. Bibliometric analysis of peer-reviewed literature on antimicrobial stewardship from 1990 to 2019. Global Health. 2021;17(1):1.PubMedPubMedCentral Sweileh WM. Bibliometric analysis of peer-reviewed literature on antimicrobial stewardship from 1990 to 2019. Global Health. 2021;17(1):1.PubMedPubMedCentral
52.
Zurück zum Zitat Briones-Bitar J, Carrión-Mero P, Montalván-Burbano N, Morante-Carballo F. Rockfall research: a bibliometric analysis and future trends. Geosciences. 2020;10(10):403. Briones-Bitar J, Carrión-Mero P, Montalván-Burbano N, Morante-Carballo F. Rockfall research: a bibliometric analysis and future trends. Geosciences. 2020;10(10):403.
53.
Zurück zum Zitat Falagas ME, Pitsouni EI, Malietzis GA, Pappas G. Comparison of PubMed, Scopus, Web of Science, and Google Scholar: strengths and weaknesses. FASEB J. 2008;22(2):338–42.PubMed Falagas ME, Pitsouni EI, Malietzis GA, Pappas G. Comparison of PubMed, Scopus, Web of Science, and Google Scholar: strengths and weaknesses. FASEB J. 2008;22(2):338–42.PubMed
54.
Zurück zum Zitat Kulkarni AV, Aziz B, Shams I, Busse JW. Comparisons of citations in Web of Science, Scopus, and Google Scholar for articles published in general medical journals. JAMA. 2009;302(10):1092–6.PubMed Kulkarni AV, Aziz B, Shams I, Busse JW. Comparisons of citations in Web of Science, Scopus, and Google Scholar for articles published in general medical journals. JAMA. 2009;302(10):1092–6.PubMed
55.
Zurück zum Zitat Mongeon P, Paul-Hus A. The journal coverage of Web of Science and Scopus: a comparative analysis. Scientometrics. 2015;106(1):213–28. Mongeon P, Paul-Hus A. The journal coverage of Web of Science and Scopus: a comparative analysis. Scientometrics. 2015;106(1):213–28.
56.
Zurück zum Zitat Ahn J, Sinha R, Pei Z, Dominianni C, Wu J, Shi J, Goedert JJ, Hayes RB, Yang L. Human gut microbiome and risk for colorectal cancer. J Natl Cancer Inst. 2013;105(24):1907–11.PubMedPubMedCentral Ahn J, Sinha R, Pei Z, Dominianni C, Wu J, Shi J, Goedert JJ, Hayes RB, Yang L. Human gut microbiome and risk for colorectal cancer. J Natl Cancer Inst. 2013;105(24):1907–11.PubMedPubMedCentral
57.
Zurück zum Zitat Berkovic MC, Cigrovski V, Bilic-Curcic I, Mrzljak A. What is the gut feeling telling us about physical activity in colorectal carcinogenesis? World J Clin Cases. 2020;8(23):5844–51.PubMedPubMedCentral Berkovic MC, Cigrovski V, Bilic-Curcic I, Mrzljak A. What is the gut feeling telling us about physical activity in colorectal carcinogenesis? World J Clin Cases. 2020;8(23):5844–51.PubMedPubMedCentral
58.
Zurück zum Zitat Contreras AV, Cocom-Chan B, Hernandez-Montes G, Portillo-Bobadilla T, Resendis-Antonio O. Host-microbiome interaction and cancer: potential application in precision medicine. Front Physiol. 2016;7:606.PubMedPubMedCentral Contreras AV, Cocom-Chan B, Hernandez-Montes G, Portillo-Bobadilla T, Resendis-Antonio O. Host-microbiome interaction and cancer: potential application in precision medicine. Front Physiol. 2016;7:606.PubMedPubMedCentral
59.
Zurück zum Zitat Gupta A, Saha S, Khanna S. Therapies to modulate gut microbiota: past, present and future. World J Gastroenterol. 2020;26(8):777–88.PubMedPubMedCentral Gupta A, Saha S, Khanna S. Therapies to modulate gut microbiota: past, present and future. World J Gastroenterol. 2020;26(8):777–88.PubMedPubMedCentral
60.
Zurück zum Zitat Huang QY, Yao F, Zhou CR, Huang XY, Wang Q, Long H, Wu QM. Role of gut microbiome in regulating the effectiveness of metformin in reducing colorectal cancer in type 2 diabetes. World J Clin Cases. 2020;8(24):6213–28.PubMedPubMedCentral Huang QY, Yao F, Zhou CR, Huang XY, Wang Q, Long H, Wu QM. Role of gut microbiome in regulating the effectiveness of metformin in reducing colorectal cancer in type 2 diabetes. World J Clin Cases. 2020;8(24):6213–28.PubMedPubMedCentral
61.
Zurück zum Zitat Malla MA, Dubey A, Kumar A, Yadav S, Hashem A, Abd Allah EF. Exploring the human microbiome: the potential future role of next-generation sequencing in disease diagnosis and treatment. Front Immunol. 2018;9:2868.PubMed Malla MA, Dubey A, Kumar A, Yadav S, Hashem A, Abd Allah EF. Exploring the human microbiome: the potential future role of next-generation sequencing in disease diagnosis and treatment. Front Immunol. 2018;9:2868.PubMed
62.
Zurück zum Zitat Roy S, Trinchieri G. Microbiota: a key orchestrator of cancer therapy. Nat Rev Cancer. 2017;17(5):271–85.PubMed Roy S, Trinchieri G. Microbiota: a key orchestrator of cancer therapy. Nat Rev Cancer. 2017;17(5):271–85.PubMed
63.
Zurück zum Zitat Sabit H, Cevik E, Tombuloglu H. Colorectal cancer: the epigenetic role of microbiome. World J Clin Cases. 2019;7(22):3683–97.PubMedPubMedCentral Sabit H, Cevik E, Tombuloglu H. Colorectal cancer: the epigenetic role of microbiome. World J Clin Cases. 2019;7(22):3683–97.PubMedPubMedCentral
64.
65.
Zurück zum Zitat Tlaskalová-Hogenová H, Stěpánková R, Kozáková H, Hudcovic T, Vannucci L, Tučková L, Rossmann P, Hrnčíř T, Kverka M, Zákostelská Z, et al. The role of gut microbiota (commensal bacteria) and the mucosal barrier in the pathogenesis of inflammatory and autoimmune diseases and cancer: contribution of germ-free and gnotobiotic animal models of human diseases. Cell Mol Immunol. 2011;8(2):110–20.PubMedPubMedCentral Tlaskalová-Hogenová H, Stěpánková R, Kozáková H, Hudcovic T, Vannucci L, Tučková L, Rossmann P, Hrnčíř T, Kverka M, Zákostelská Z, et al. The role of gut microbiota (commensal bacteria) and the mucosal barrier in the pathogenesis of inflammatory and autoimmune diseases and cancer: contribution of germ-free and gnotobiotic animal models of human diseases. Cell Mol Immunol. 2011;8(2):110–20.PubMedPubMedCentral
66.
Zurück zum Zitat Wei AL, Li M, Li GQ, Wang X, Hu WM, Li ZL, Yuan J, Liu HY, Zhou LL, Li K, et al. Oral microbiome and pancreatic cancer. World J Gastroenterol. 2020;26(48):7679–92.PubMedPubMedCentral Wei AL, Li M, Li GQ, Wang X, Hu WM, Li ZL, Yuan J, Liu HY, Zhou LL, Li K, et al. Oral microbiome and pancreatic cancer. World J Gastroenterol. 2020;26(48):7679–92.PubMedPubMedCentral
67.
Zurück zum Zitat Wollowski I, Rechkemmer G, Pool-Zobel BL. Protective role of probiotics and prebiotics in colon cancer. Am J Clin Nutr. 2001;73(2 Suppl):451s–5s.PubMed Wollowski I, Rechkemmer G, Pool-Zobel BL. Protective role of probiotics and prebiotics in colon cancer. Am J Clin Nutr. 2001;73(2 Suppl):451s–5s.PubMed
68.
Zurück zum Zitat Zeller G, Tap J, Voigt AY, Sunagawa S, Kultima JR, Costea PI, Amiot A, Böhm J, Brunetti F, Habermann N, et al. Potential of fecal microbiota for early-stage detection of colorectal cancer. Mol Syst Biol. 2014;10(11):766.PubMedPubMedCentral Zeller G, Tap J, Voigt AY, Sunagawa S, Kultima JR, Costea PI, Amiot A, Böhm J, Brunetti F, Habermann N, et al. Potential of fecal microbiota for early-stage detection of colorectal cancer. Mol Syst Biol. 2014;10(11):766.PubMedPubMedCentral
69.
Zurück zum Zitat Elkrief A, Derosa L, Zitvogel L, Kroemer G, Routy B. The intimate relationship between gut microbiota and cancer immunotherapy. Gut Microbes. 2019;10(3):424–8.PubMed Elkrief A, Derosa L, Zitvogel L, Kroemer G, Routy B. The intimate relationship between gut microbiota and cancer immunotherapy. Gut Microbes. 2019;10(3):424–8.PubMed
70.
Zurück zum Zitat Kujawska M, Jodynis-Liebert J. Potential of the ellagic acid-derived gut microbiota metabolite—Urolithin A in gastrointestinal protection. World J Gastroenterol. 2020;26(23):3170–81.PubMedPubMedCentral Kujawska M, Jodynis-Liebert J. Potential of the ellagic acid-derived gut microbiota metabolite—Urolithin A in gastrointestinal protection. World J Gastroenterol. 2020;26(23):3170–81.PubMedPubMedCentral
71.
Zurück zum Zitat Russo E, Nannini G, Dinu M, Pagliai G, Sofi F, Amedei A. Exploring the food-gut axis in immunotherapy response of cancer patients. World J Gastroenterol. 2020;26(33):4919–32.PubMedPubMedCentral Russo E, Nannini G, Dinu M, Pagliai G, Sofi F, Amedei A. Exploring the food-gut axis in immunotherapy response of cancer patients. World J Gastroenterol. 2020;26(33):4919–32.PubMedPubMedCentral
72.
Zurück zum Zitat Yan C, Tu XX, Wu W, Tong Z, Liu LL, Zheng Y, Jiang WQ, Zhao P, Fang WJ, Zhang HY. Antibiotics and immunotherapy in gastrointestinal tumors: friend or foe? World J Clin Cases. 2019;7(11):1253–61.PubMedPubMedCentral Yan C, Tu XX, Wu W, Tong Z, Liu LL, Zheng Y, Jiang WQ, Zhao P, Fang WJ, Zhang HY. Antibiotics and immunotherapy in gastrointestinal tumors: friend or foe? World J Clin Cases. 2019;7(11):1253–61.PubMedPubMedCentral
73.
Zurück zum Zitat Yi M, Jiao D, Qin S, Chu Q, Li A, Wu K. Manipulating gut microbiota composition to enhance the therapeutic effect of cancer immunotherapy. Integr Cancer Ther. 2019;18:1534735419876351.PubMedPubMedCentral Yi M, Jiao D, Qin S, Chu Q, Li A, Wu K. Manipulating gut microbiota composition to enhance the therapeutic effect of cancer immunotherapy. Integr Cancer Ther. 2019;18:1534735419876351.PubMedPubMedCentral
Metadaten
Titel
Global research trends on the links between the gut microbiome and cancer: a visualization analysis
verfasst von
Sa’ed H. Zyoud
Samah W. Al-Jabi
Riad Amer
Muna Shakhshir
Moyad Shahwan
Ammar A. Jairoun
Maha Akkawi
Adham Abu Taha
Publikationsdatum
01.12.2022
Verlag
BioMed Central
Erschienen in
Journal of Translational Medicine / Ausgabe 1/2022
Elektronische ISSN: 1479-5876
DOI
https://doi.org/10.1186/s12967-022-03293-y

Weitere Artikel der Ausgabe 1/2022

Journal of Translational Medicine 1/2022 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Echinokokkose medikamentös behandeln oder operieren?

06.05.2024 DCK 2024 Kongressbericht

Die Therapie von Echinokokkosen sollte immer in spezialisierten Zentren erfolgen. Eine symptomlose Echinokokkose kann – egal ob von Hunde- oder Fuchsbandwurm ausgelöst – konservativ erfolgen. Wenn eine Op. nötig ist, kann es sinnvoll sein, vorher Zysten zu leeren und zu desinfizieren. 

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Proximale Humerusfraktur: Auch 100-Jährige operieren?

01.05.2024 DCK 2024 Kongressbericht

Mit dem demographischen Wandel versorgt auch die Chirurgie immer mehr betagte Menschen. Von Entwicklungen wie Fast-Track können auch ältere Menschen profitieren und bei proximaler Humerusfraktur können selbst manche 100-Jährige noch sicher operiert werden.

Die „Zehn Gebote“ des Endokarditis-Managements

30.04.2024 Endokarditis Leitlinie kompakt

Worauf kommt es beim Management von Personen mit infektiöser Endokarditis an? Eine Kardiologin und ein Kardiologe fassen die zehn wichtigsten Punkte der neuen ESC-Leitlinie zusammen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.